Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Others

Ratios

Senti Biosciences (SNTI) Other financing activities (2021 - 2025)

Senti Biosciences has reported Other financing activities over the past 3 years, most recently at $12000.0 for Q3 2025.

For Q3 2025, Other financing activities changed N/A year-over-year to $12000.0; the TTM value through Dec 2025 reached $2.5 million, up 978.17%, while the annual FY2025 figure was $2.5 million, 2369.0% up from the prior year.
Other financing activities for Q3 2025 was $12000.0 at Senti Biosciences, down from $533000.0 in the prior quarter.
Over five years, Other financing activities peaked at $1.9 million in Q1 2025 and troughed at $12000.0 in Q3 2025.
A 3-year average of $609755.7 and a median of $523430.0 in 2021 define the central range for Other financing activities.